Literature DB >> 17572189

Characteristics of infections in patients undergoing staged implantation for sacral nerve stimulation.

Michael L Guralnick1, Saraleen Benouni, R Corey O'Connor, Charles Edmiston.   

Abstract

OBJECTIVES: To review clinical and surgical factors in patients who have undergone staged sacral nerve stimulator implantation and to determine whether there are any identifiable risk factors for infection.
METHODS: A retrospective chart review was performed on 76 consecutive patients undergoing staged implantation for sacral nerve stimulation for voiding dysfunction. Patients with postprocedural wound infections (after Stage 1 or Stage 2) were compared with those without infections with regard to demographic factors and surgical characteristics, such as operative time and duration of exposed lead wire. Organisms cultured were also documented.
RESULTS: Lead infection occurred in 9 of 76 patients (12%). All cultures grew Staphylococcus aureus. Of 9 patients with lead infection, 6 had organisms sensitive to their perioperative antibiotic. Forty-five patients had an implantable pulse generator implanted, and 5 infections occurred (11%). Four cultures grew S. aureus (all sensitive to the perioperative antibiotic given), whereas one grew Pseudomonas. The only significant difference in clinical/surgical characteristics between infected and noninfected patients was a longer operative time for Stage 2 in infected patients. In addition, 3 patients with infection had one or more known risk factors for wound infection (steroid use, severe psoriasis, recurrent skin abscess).
CONCLUSIONS: Apart from known risk factors for surgical wound infections, the only variable we could identify that might increase the risk for infection is a longer operative time for Stage 2. S. aureus was the organism most commonly cultured. Often it was sensitive to the perioperative antibiotic prophylaxis.

Entities:  

Mesh:

Year:  2007        PMID: 17572189     DOI: 10.1016/j.urology.2007.01.099

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  13 in total

Review 1.  A systematic review of clinical studies of electrical stimulation for treatment of lower urinary tract dysfunction.

Authors:  Ash K Monga; Michael R Tracey; Jeyakumar Subbaroyan
Journal:  Int Urogynecol J       Date:  2012-03-17       Impact factor: 2.894

2.  Infection rates in a large investigational trial of sacral nerve stimulation for fecal incontinence.

Authors:  Steven D Wexner; Tracy Hull; Yair Edden; John A Coller; Ghislain Devroede; Richard McCallum; Miranda Chan; Jennifer M Ayscue; Abbas S Shobeiri; David Margolin; Michael England; Howard Kaufman; William J Snape; Ece Mutlu; Heidi Chua; Paul Pettit; Deborah Nagle; Robert D Madoff; Darin R Lerew; Anders Mellgren
Journal:  J Gastrointest Surg       Date:  2010-03-31       Impact factor: 3.452

3.  Surgery: centers of excellence for penile prosthesis: yes or no?

Authors:  Tariq F Al-Shaiji; Gerald B Brock
Journal:  Nat Rev Urol       Date:  2009-07       Impact factor: 14.432

Review 4.  Sacral Neuromodulation Implant Infection: Risk Factors and Prevention.

Authors:  Calvin Lee; Javier Pizarro-Berdichevsky; Marisa M Clifton; Sandip P Vasavada
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

5.  Presacral abscess as a rare complication of sacral nerve stimulator implantation.

Authors:  A Gumber; S Ayyar; H Varia; S Pettit
Journal:  Ann R Coll Surg Engl       Date:  2017-01-10       Impact factor: 1.891

6.  [Sacral neuromodulation in urology. The emperor's new clothes or effective high-tech medicine?].

Authors:  M R Hoda; P Fornara
Journal:  Urologe A       Date:  2010-10       Impact factor: 0.639

Review 7.  Infection Rates of Electrical Leads Used for Percutaneous Neurostimulation of the Peripheral Nervous System.

Authors:  Brian M Ilfeld; Rodney A Gabriel; Michael F Saulino; John Chae; P Hunter Peckham; Stuart A Grant; Christopher A Gilmore; Michael C Donohue; Matthew G deBock; Amorn Wongsarnpigoon; Joseph W Boggs
Journal:  Pain Pract       Date:  2016-11-11       Impact factor: 3.183

8.  Troubleshooting sacral neuromodulation issues.

Authors:  Maude E Carmel; Sandip P Vasavada; Howard B Goldman
Journal:  Curr Urol Rep       Date:  2012-10       Impact factor: 3.092

9.  Differences in sacral neuromodulation device infection rates based on preoperative antibiotic selection.

Authors:  Allen M Haraway; J Quentin Clemens; Chang He; Cynthia Stroup; Humphrey O Atiemo; Anne P Cameron
Journal:  Int Urogynecol J       Date:  2013-05-22       Impact factor: 2.894

10.  Sacral neuromodulation for bowel dysfunction: a consensus statement from the Italian group.

Authors:  E Falletto; E Ganio; G Naldini; C Ratto; D F Altomare
Journal:  Tech Coloproctol       Date:  2013-04-06       Impact factor: 3.781

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.